Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02777593 · ClinicalTrials.gov registry record · NA

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

A NA study of Aortic Aneurysm, Thoracic and Aorta; Lesion, sponsored by W.L.Gore & Associates.

Active
Registry status
NA
Development phase
250
Enrollment target
20
Study locations

NCT02777593: Active NA study of Aortic Aneurysm, Thoracic and Aorta; Lesion, sponsored by W.L.Gore & Associates.

NCT02777593 is a NA study of Aortic Aneurysm, Thoracic and Aorta; Lesion that is active but no longer recruiting, run by W.L.Gore & Associates. The registered enrollment target is 250 participants, above the 183-participant average among 4 other Aortic Aneurysm, Thoracic trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02777593, a NA study of Aortic Aneurysm, Thoracic and Aorta; Lesion, is active but no longer recruiting, sponsored by W.L.Gore & Associates.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta, requiring Zone 2 proximal implantation of the device.

Primary Outcome

Primary Endpoint was composite of the following events: device technical success and absence of aortic rupture, lesion-related mortality, disabling stroke, permanent paraplegia, permanent paraparesis, new onset renal failure requiring permanent dialysis, additional unanticipated post-procedural surgical or interventional procedure related to the device/procedure/withdrawal of the delivery system. Limited to 30 days: disabling stroke, permanent paraplegia, permanent paraparesis, new onset renal f

Interventions

  • DEVICE GORE® TAG® Thoracic Branch Endoprosthesis

Study Locations (20)

California

  • Keck Medical Center of USC - Los Angeles
  • Cedar-Sinai Medical Center - Los Angeles
  • Leland Stanford Junior University - Stanford

Florida

  • University of Florida - Gainesville - Gainesville
  • Univeristy of South Florida - Tampa

Connecticut

  • Hartford Hospital - Hartford

District of Columbia

  • MedStar Health Research Institute - Washington D.C.

Georgia

  • Emory University - Atlanta

Illinois

  • Northwestern University - Chicago

Indiana

  • St. Vincent Medical Group, Inc. - Indianapolis

Kentucky

  • University of Louisville Jewish Hospital - Louisville

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2016-09-06
Est. Completion 2027-12
Phase NA
W.L.Gore & Associates

53 total trials

What the registry record for NCT02777593 still lists

NCT02777593 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 183-participant average among 4 other Aortic Aneurysm, Thoracic trials with a reported enrollment target (37% higher).

The record links to 2 conditions, with Aortic Aneurysm, Thoracic appearing as the primary indexed condition, and to 1 intervention - of which GORE® TAG® Thoracic Branch Endoprosthesis is the first listed.

NCT02777593 names 20 study sites across 17 states, led by California, Florida, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02777593 about?

NCT02777593 is a clinical study titled "Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2". The objective of this study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta, requiring Zone 2 proximal implantation of the device.

What is the current status of trial NCT02777593?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2016-09-06. Estimated completion is 2027-12.

What conditions does trial NCT02777593 study?

This clinical trial studies the following conditions: Aortic Aneurysm, Thoracic, Aorta; Lesion.

What interventions are being tested in trial NCT02777593?

The interventions under investigation include: GORE® TAG® Thoracic Branch Endoprosthesis (DEVICE).

Who is sponsoring clinical trial NCT02777593?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02777593 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Aneurysm, Thoracic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02777593, the US trial registry maintained by the National Library of Medicine. NCT02777593 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.